IMUX Key Statistics, Chart & Performance
The current stock price of IMUX is 0.583 USD. In the past month the price decreased by -10.31%. In the past year, price decreased by -47%.
IMUX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About IMUX
Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Company Info
IMMUNIC INC
1200 Avenue Of The Americas, Suite 200
New York City NEW YORK 10036 US
CEO: Daniel Vitt
Employees: 91
Phone: 13322559818
IMMUNIC INC / IMUX FAQ
Can you describe the business of IMMUNIC INC?
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Can you provide the latest stock price for IMMUNIC INC?
The current stock price of IMUX is 0.583 USD. The price increased by 9.24% in the last trading session.
What is the dividend status of IMMUNIC INC?
IMUX does not pay a dividend.
What is the ChartMill rating of IMMUNIC INC stock?
IMUX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for IMUX stock?
15 analysts have analysed IMUX and the average price target is 5.48 USD. This implies a price increase of 840.39% is expected in the next year compared to the current price of 0.583.
Would investing in IMMUNIC INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMUX.
Can you provide the upcoming earnings date for IMMUNIC INC?
IMMUNIC INC (IMUX) will report earnings on 2026-02-19, after the market close.
IMUX Technical Analysis
IMUX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMUX. The financial health of IMUX is average, but there are quite some concerns on its profitability.
IMUX Financial Highlights
Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 32.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -253.16% | ||
| ROE | -981.49% | ||
| Debt/Equity | 0 |
IMUX Forecast & Estimates
15 analysts have analysed IMUX and the average price target is 5.48 USD. This implies a price increase of 840.39% is expected in the next year compared to the current price of 0.583.